# OnCo record nct06361888 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06361888/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06361888", "NCT06361888" ;
  schema:name "A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer"@en ;
  schema:description "A phase 2/3 trial of Gemcitabine and Camrelizumab in pancreatic ductal adenocarcinoma, run by Hutchmed, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06361888/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06361888> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2/3" ;
  schema:startDate "2024-05-08" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/surufatinib/> ;
  onco:companies <https://onco.cc/companies/hutchmed/> .